- Home
- NL vs FHTX Comparison
NL vs FHTX Comparison
Compare NL & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NL
- FHTX
- Stock Information
- Founded
- NL 1891
- FHTX 2015
- Country
- NL United States
- FHTX United States
- Employees
- NL N/A
- FHTX N/A
- Industry
- NL Major Chemicals
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NL Industrials
- FHTX Health Care
- Exchange
- NL Nasdaq
- FHTX Nasdaq
- Market Cap
- NL 320.5M
- FHTX 278.1M
- IPO Year
- NL N/A
- FHTX 2020
- Fundamental
- Price
- NL $6.36
- FHTX $5.77
- Analyst Decision
- NL Sell
- FHTX Strong Buy
- Analyst Count
- NL 1
- FHTX 6
- Target Price
- NL $6.00
- FHTX $11.33
- AVG Volume (30 Days)
- NL 23.5K
- FHTX 84.1K
- Earning Date
- NL 11-05-2025
- FHTX 11-03-2025
- Dividend Yield
- NL 5.65%
- FHTX N/A
- EPS Growth
- NL 141.37
- FHTX N/A
- EPS
- NL 1.10
- FHTX N/A
- Revenue
- NL $152,721,000.00
- FHTX $24,173,000.00
- Revenue This Year
- NL $15.75
- FHTX $43.75
- Revenue Next Year
- NL $2.44
- FHTX $1.27
- P/E Ratio
- NL $5.81
- FHTX N/A
- Revenue Growth
- NL N/A
- FHTX N/A
- 52 Week Low
- NL $5.29
- FHTX $2.95
- 52 Week High
- NL $9.42
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NL 47.60
- FHTX 58.68
- Support Level
- NL $6.50
- FHTX $5.14
- Resistance Level
- NL $6.64
- FHTX $5.46
- Average True Range (ATR)
- NL 0.30
- FHTX 0.37
- MACD
- NL 0.01
- FHTX 0.05
- Stochastic Oscillator
- NL 38.67
- FHTX 99.03
About NL NL Industries Inc.
NL Industries Inc is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.